Summarized by Masters of Longevity from PR Newswire.
An update-style article presenting early human clinical data on a novel in vivo CAR-T therapy for multiple myeloma, highlighting study design and reported safety and response signals.
Key Takeaways
- A single intravenous dose of the in vivo CAR-T therapy produced functional BCMA CAR-T cells without lymphodepleting chemotherapy.
- Among 10 efficacy-evaluable patients the objective response rate was 90% and MRD negativity was 90%.
- In the high-dose cohort both ORR and MRD negativity reached 100% with no reported DLTs, ICANS, or treatment-related deaths.
